Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-27T01:19:32.254Z Has data issue: false hasContentIssue false
  • English
  • Français

Recurrent PNET with MGMT Methylation Responds to Temozolomide

Published online by Cambridge University Press:  02 December 2014

Jiwon Oh ,
Juan M. Bilbao ,
May N. Tsao ,
Mahmood Fazl ,
Marie-Christine Guiot ,
Rolando F. Del Maestro  and
James R. Perry
Jiwon Oh*
Affiliation:
Divison of Neurology, Sunnybrook Health Sciences Centre, Toronto, Ontario
Juan M. Bilbao
Affiliation:
Odette Cancer Centre, Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario
May N. Tsao
Affiliation:
Departments of Medicine, and Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario
Mahmood Fazl
Affiliation:
Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, Ontario
Marie-Christine Guiot
Affiliation:
Department of Pathology, Brain Tumour Research Centre, Montreal Neurological Insititute and Hospital, McGill University, Montreal, Quebec, Canada Department of Neurosurgery, Brain Tumour Research Centre, Montreal Neurological Insititute and Hospital, McGill University, Montreal, Quebec, Canada
Rolando F. Del Maestro
Affiliation:
Department of Neurosurgery, Brain Tumour Research Centre, Montreal Neurological Insititute and Hospital, McGill University, Montreal, Quebec, Canada
James R. Perry
Affiliation:
Divison of Neurology, Sunnybrook Health Sciences Centre, Toronto, Ontario
*
University of Toronto, c/o Office of Dr. James Perry Sunnybrook Health Sciences Centre, A402, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Communications
Information
Canadian Journal of Neurological Sciences , Volume 36 , Issue 5 , September 2009 , pp. 654 - 657
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1.Rao, RD, Robins, HI, Mehta, MP.Late recurrence of a primitive neuro-ectodermal tumor. Oncology. 2001;61: 189–91.Google Scholar
2.Ohba, S, Yoshida, K, Hirose, Y, Ikeda, E, Kawase, T.A supratentorial primitive neuroectodermal tumor in an adult: a case report and review of the literature. J Neurooncol. 2008;86(2):217–24.CrossRefGoogle Scholar
3.Kim, DG, Lee, DY, Paek, SH, Chi, JG, Choe, G, Jung, HW.Supratentorial primitive neuroectodermal tumors in adults. J Neurooncol. 2002;60: 43–52.CrossRefGoogle ScholarPubMed
4.Terheggen, F, Troost, D, Majoie, CB, Leenstra, S, Richel, DJ.Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide. J Neurooncol. 2007;82: 113–6.CrossRefGoogle Scholar
5.Brandes, AA, Palmisano, V, Monfardini, S.Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev. 1999;25: 3–12.Google Scholar
6.Durando, X, Thivat, E, Gilliot, O, Irthum, B, Verrelle, P, Vincent, C, et al.Temozolomide treatment of an adult with a relapsing medulloblastoma. Cancer Invest. 2007;25: 470–5.Google Scholar
7.Poelen, J, Bernsen, HJ, Prick, MJ.Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg. 2007;107: 51–4.Google Scholar
8.Herrlinger, U, Steinbrecher, A, Rieger, J, Hau, P, Kortmann, RD, Meyermann, R, et al.Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol. 2005;252: 291–9.Google Scholar
9.O’Reilly, SM, Newlands, ES, Glaser, MG, Brampton, M, Rice-Edwards, JM, Illingworth, RD, et al.Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7): 940–2.Google Scholar
10.Hegi, ME, Diserens, AC, Gorlia, T, Hamou, MF, de Tribolet, N, Weller, M, et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997–1003.Google Scholar
11.Kovacs, K, Scheithauer, BW, Lombardero, M, McLendon, RE, Syro, LV, Uribe, H, et al.MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008;115: 261–2.Google Scholar